vs
Side-by-side financial comparison of AbbVie (ABBV) and Wellgistics Health, Inc. (WGRX). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $1.7M, roughly 9947.0× Wellgistics Health, Inc.). AbbVie runs the higher net margin — 10.9% vs -1667.2%, a 1678.1% gap on every dollar of revenue.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Wellgistics Health, Inc. is a U.S.-headquartered healthcare services firm focused on the distribution of prescription pharmaceuticals, over-the-counter medications, and medical supplies. Its key customer segments include retail pharmacies, long-term care facilities, and independent healthcare providers across the domestic market.
ABBV vs WGRX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $1.7M |
| Net Profit | $1.8B | $-27.9M |
| Gross Margin | 72.6% | -470.2% |
| Operating Margin | 27.3% | -1517.5% |
| Net Margin | 10.9% | -1667.2% |
| Revenue YoY | 10.0% | — |
| Net Profit YoY | 8354.5% | — |
| EPS (diluted) | $1.02 | $-0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $1.7M | ||
| Q3 25 | $15.8B | $3.0M | ||
| Q2 25 | $15.4B | $7.8M | ||
| Q1 25 | $13.3B | $10.9M | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | — | ||
| Q1 24 | $12.3B | — |
| Q4 25 | $1.8B | $-27.9M | ||
| Q3 25 | $186.0M | $-34.3M | ||
| Q2 25 | $938.0M | $-6.7M | ||
| Q1 25 | $1.3B | $-32.4M | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | 72.6% | -470.2% | ||
| Q3 25 | 66.4% | 7.7% | ||
| Q2 25 | 71.8% | 6.5% | ||
| Q1 25 | 70.0% | 6.4% | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | -1517.5% | ||
| Q3 25 | 12.1% | -1047.1% | ||
| Q2 25 | 31.7% | -70.6% | ||
| Q1 25 | 28.0% | -288.6% | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | — | ||
| Q1 24 | 22.7% | — |
| Q4 25 | 10.9% | -1667.2% | ||
| Q3 25 | 1.2% | -1139.0% | ||
| Q2 25 | 6.1% | -85.6% | ||
| Q1 25 | 9.6% | -298.5% | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 11.1% | — |
| Q4 25 | $1.02 | $-0.24 | ||
| Q3 25 | $0.10 | $-0.46 | ||
| Q2 25 | $0.52 | $-0.11 | ||
| Q1 25 | $0.72 | $-0.62 | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $42.6K |
| Total DebtLower is stronger | $58.9B | $23.5M |
| Stockholders' EquityBook value | $-3.3B | $-12.4M |
| Total Assets | $134.0B | $30.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $42.6K | ||
| Q3 25 | $5.7B | $4.2M | ||
| Q2 25 | $6.5B | $419.9K | ||
| Q1 25 | $5.2B | $2.5M | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $13.2B | — | ||
| Q1 24 | $18.1B | — |
| Q4 25 | $58.9B | $23.5M | ||
| Q3 25 | $63.0B | $24.8M | ||
| Q2 25 | $63.0B | $23.3M | ||
| Q1 25 | $64.5B | $24.1M | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
| Q4 25 | $-3.3B | $-12.4M | ||
| Q3 25 | $-2.6B | $6.8M | ||
| Q2 25 | $-183.0M | $905.3K | ||
| Q1 25 | $1.4B | $4.5M | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $8.0B | — |
| Q4 25 | $134.0B | $30.5M | ||
| Q3 25 | $133.9B | $52.8M | ||
| Q2 25 | $137.2B | $54.2M | ||
| Q1 25 | $136.2B | $58.1M | ||
| Q4 24 | $135.2B | — | ||
| Q3 24 | $143.4B | — | ||
| Q2 24 | $141.9B | — | ||
| Q1 24 | $148.9B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.66× | ||
| Q2 25 | — | 25.72× | ||
| Q1 25 | 45.44× | 5.39× | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $-6.3M |
| Free Cash FlowOCF − Capex | $4.9B | — |
| FCF MarginFCF / Revenue | 29.4% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $-6.3M | ||
| Q3 25 | $7.0B | $-1.1M | ||
| Q2 25 | $5.2B | $-2.1M | ||
| Q1 25 | $1.6B | $-1.3M | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $4.0B | — |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
